Risk factors
Vivos Therapeutics (VVOS) risk factors
Item 1A of every Vivos Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors47 risks8 new4 dropped6 reworded
Vivos expanded its business model through the SCN acquisition, financing it with an $8.25 million Streeterville note and significant equity issuance.
Filed Apr 15, 2026 - FY2024 10-K risk factors43 risks
Operating losses and negative cash flows dominate our risks, alongside reliance on The Vivos Method and stringent FDA medical device regulations.
Filed Mar 31, 2025